Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Nezam Hassan Afdhal, M.D.


The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. U01AT003571 (AFDHAL, NEZAM HASSAN) Aug 15, 2006 - Jul 31, 2011
    Clinical Center for Phase I/II trials of Silymarin in Chronic Liver Disease
    Role: Principal Investigator
  2. U19AI066313 (SCHUPPAN, DETLEF) Jun 30, 2005 - Nov 28, 2010
    Determinants of Liver Injury in Chronic Hepatitis C Virus Infection
    Role: Co-Principal Investigator
  3. R21CA108303 (AFDHAL, NEZAM HASSAN) Sep 25, 2003 - Aug 31, 2005
    Proteomics and Biomarkers for Hepatocellular Cancer
    Role: Principal Investigator
  4. U01DK060340 (AFDHAL, NEZAM HASSAN) Aug 21, 2001 - Jun 30, 2006
    Antiviral Therapy in African Americans with HCV
    Role: Principal Investigator
  5. R01DK045936 (AFDHAL, NEZAM HASSAN) Jul 15, 1993 - May 31, 2003
    Role: Principal Investigator

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Ezaz G, Trivedi HD, Connelly MA, Filozof C, Howard K, L Parrish M, Kim M, Herman MA, Nasser I, Afdhal NH, Jiang ZG, Lai M. Differential Associations of Circulating MicroRNAs With Pathogenic Factors in NAFLD. Hepatol Commun. 2020 May; 4(5):670-680. PMID: 32363318.
  2. Navarro VJ, Belle SH, D'Amato M, Afdhal N, Brunt EM, Fried MW, Rajender Reddy K, Wahed AS, Harrison S. Correction: Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial. PLoS One. 2019; 14(10):e0223915. PMID: 31600349.
  3. Tsertsvadze T, Gamkrelidze A, Chkhartishvili N, Abutidze A, Sharvadze L, Kerashvili V, Butsashvili M, Metreveli D, Gvinjilia L, Shadaker S, Nasrullah M, Adamia E, Zeuzem S, Afdhal N, Arora S, Thornton K, Skaggs B, Kuchuloria T, Lagvilava M, Sergeenko D, Averhoff F. Three years of progress towards achieving hepatitis C elimination in the country of Georgia, April 2015 - March 2018. Clin Infect Dis. 2019 Sep 29. PMID: 31563938.
  4. Anstee QM, Lawitz EJ, Alkhouri N, Wong VW, Romero-Gomez M, Okanoue T, Trauner M, Kersey K, Li G, Han L, Jia C, Wang L, Chen G, Subramanian GM, Myers RP, Djedjos CS, Kohli A, Bzowej N, Younes Z, Sarin S, Shiffman ML, Harrison SA, Afdhal NH, Goodman Z, Younossi ZM. Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials. Hepatology. 2019 11; 70(5):1521-1530. PMID: 31271665.
  5. Sasaki R, Shiino C, Imawari M, Bentley R, Cai B, Yoshida M, Afdhal N. Safety and effectiveness of lusutrombopag in Japanese chronic liver disease patients with thrombocytopenia undergoing invasive procedures: Interim results of a postmarketing surveillance. Hepatol Res. 2019 Oct; 49(10):1169-1181. PMID: 31228221.
  6. Tsai N, Bacon B, Curry M, Flamm SL, Milligan S, Wick N, Younossi Z, Afdhal N. Changing demographics among populations prescribed HCV treatment, 2013-2017. Am J Manag Care. 2019 07; 25(7):319-323. PMID: 31318504.
  7. Sanyal AJ, Harrison SA, Ratziu V, Abdelmalek MF, Diehl AM, Caldwell S, Shiffman ML, Aguilar Schall R, Jia C, McColgan B, Djedjos CS, McHutchison JG, Subramanian GM, Myers RP, Younossi Z, Muir AJ, Afdhal NH, Bosch J, Goodman Z. The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. Hepatology. 2019 12; 70(6):1913-1927. PMID: 30993748.
  8. Lai M, Afdhal NH. Liver Fibrosis Determination. Gastroenterol Clin North Am. 2019 06; 48(2):281-289. PMID: 31046975.
  9. Peck-Radosavljevic M, Simon K, Iacobellis A, Hassanein T, Kayali Z, Tran A, Makara M, Ben Ari Z, Braun M, Mitrut P, Yang SS, Akdogan M, Pirisi M, Duggal A, Ochiai T, Motomiya T, Kano T, Nagata T, Afdhal N. Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2). Hepatology. 2019 10; 70(4):1336-1348. PMID: 30762895.
  10. Muir AJ, Levy C, Janssen HLA, Montano-Loza AJ, Shiffman ML, Caldwell S, Luketic V, Ding D, Jia C, McColgan BJ, McHutchison JG, Mani Subramanian G, Myers RP, Manns M, Chapman R, Afdhal NH, Goodman Z, Eksteen B, Bowlus CL. Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease. Hepatology. 2019 02; 69(2):684-698. PMID: 30153359.
    Citations:    Fields:    
  11. Danford CJ, Connelly MA, Shalaurova I, Kim M, Herman MA, Nasser I, Otvos JD, Afdhal NH, Jiang ZG, Lai M. A Pathophysiologic Approach Combining Genetics and Insulin Resistance to Predict the Severity of Nonalcoholic Fatty Liver Disease. Hepatol Commun. 2018 Dec; 2(12):1467-1478. PMID: 30556036.
  12. Jayakumar S, Middleton MS, Lawitz EJ, Mantry PS, Caldwell SH, Arnold H, Mae Diehl A, Ghalib R, Elkhashab M, Abdelmalek MF, Kowdley KV, Stephen Djedjos C, Xu R, Han L, Mani Subramanian G, Myers RP, Goodman ZD, Afdhal NH, Charlton MR, Sirlin CB, Loomba R. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib. J Hepatol. 2019 01; 70(1):133-141. PMID: 30291868.
    Citations:    Fields:    
  13. Younossi Z, Stepanova M, Sanyal AJ, Harrison SA, Ratziu V, Abdelmalek MF, Diehl AM, Caldwell S, Shiffman ML, Schall RA, McColgan B, Subramanian GM, Myers RP, Muir A, Afdhal NH, Bosch J, Goodman Z. The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. J Hepatol. 2018 12; 69(6):1365-1370. PMID: 30144554.
    Citations:    Fields:    
  14. Leahy J, O'Leary A, Afdhal N, Gray E, Milligan S, Wehmeyer MH, Walsh C. The impact of individual patient data in a network meta-analysis: An investigation into parameter estimation and model selection. Res Synth Methods. 2018 Sep; 9(3):441-469. PMID: 29923679.
    Citations: 1     Fields:    Translation:Humans
  15. Harrison SA, Abdelmalek MF, Caldwell S, Shiffman ML, Diehl AM, Ghalib R, Lawitz EJ, Rockey DC, Schall RA, Jia C, McColgan BJ, McHutchison JG, Subramanian GM, Myers RP, Younossi Z, Ratziu V, Muir AJ, Afdhal NH, Goodman Z, Bosch J, Sanyal AJ. Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. Gastroenterology. 2018 10; 155(4):1140-1153. PMID: 29990488.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  16. Babusis D, Curry MP, Kirby B, Park Y, Murakami E, Wang T, Mathias A, Afdhal N, McHutchison JG, Ray AS. Sofosbuvir and Ribavirin Liver Pharmacokinetics in Patients Infected with Hepatitis C Virus. Antimicrob Agents Chemother. 2018 05; 62(5). PMID: 29439971.
    Citations:    Fields:    
  17. Flamm SL, Bacon B, Curry MP, Milligan S, Nwankwo CU, Tsai N, Younossi Z, Afdhal N. Real-world use of elbasvir-grazoprevir in patients with chronic hepatitis C: retrospective analyses from the TRIO network. Aliment Pharmacol Ther. 2018 06; 47(11):1511-1522. PMID: 29665097.
    Citations: 1     Fields:    
  18. El-Sherif O, Jiang ZG, Tapper EB, Huang KC, Zhong A, Osinusi A, Charlton M, Manns M, Afdhal NH, Mukamal K, McHutchison J, Brainard DM, Terrault N, Curry MP. Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection. Gastroenterology. 2018 06; 154(8):2111-2121.e8. PMID: 29535028.
    Citations: 1     Fields:    Translation:HumansCells
  19. Grebely J, Feld JJ, Wyles D, Sulkowski M, Ni L, Llewellyn J, Mir HM, Sajed N, Stamm LM, Hyland RH, McNally J, Brainard DM, Jacobson I, Zeuzem S, Bourlière M, Foster G, Afdhal N, Dore GJ. Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies. Open Forum Infect Dis. 2018 Feb; 5(2):ofy001. PMID: 29450210.
  20. Loomba R, Gindin Y, Jiang Z, Lawitz E, Caldwell S, Djedjos CS, Xu R, Chung C, Myers RP, Subramanian GM, Goodman Z, Charlton M, Afdhal NH, Diehl AM. DNA methylation signatures reflect aging in patients with nonalcoholic steatohepatitis. JCI Insight. 2018 01 25; 3(2). PMID: 29367468.
    Citations: 1     Fields:    
  21. Loomba R, Lawitz E, Mantry PS, Jayakumar S, Caldwell SH, Arnold H, Diehl AM, Djedjos CS, Han L, Myers RP, Subramanian GM, McHutchison JG, Goodman ZD, Afdhal NH, Charlton MR. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. Hepatology. 2018 02; 67(2):549-559. PMID: 28892558.
    Citations: 17     Fields:    
  22. Jiang ZG, Sandhu B, Feldbrügge L, Yee EU, Csizmadia E, Mitsuhashi S, Huang J, Afdhal NH, Robson SC, Lai M. Serum Activity of Macrophage-Derived Adenosine Deaminase 2 Is Associated With Liver Fibrosis in Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2018 07; 16(7):1170-1172. PMID: 29170098.
    Citations:    Fields:    
  23. Curry MP, Tapper EB, Bacon B, Dieterich D, Flamm SL, Guest L, Kowdley KV, Lee Y, Milligan S, Tsai N, Younossi Z, Afdhal NH. Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients. Aliment Pharmacol Ther. 2017 09; 46(5):540-548. PMID: 28691377.
    Citations: 7     Fields:    Translation:HumansCells
  24. Jones M, Cunningham ME, Wing P, DeSilva S, Challa R, Sheri A, Padmanabhan S, Iyer RP, Korba BE, Afdhal N, Foster GR. SB 9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variants. J Med Virol. 2017 09; 89(9):1620-1628. PMID: 28303593.
    Citations: 3     Fields:    Translation:HumansCells
  25. Tapper EB, Afdhal NH, Curry MP. Before or After Transplantation? A Review of the Cost Effectiveness of Treating Waitlisted Patients With Hepatitis C. Transplantation. 2017 05; 101(5):933-937. PMID: 28437385.
    Citations: 4     Fields:    Translation:Humans
  26. Tapper EB, Hughes MS, Buti M, Dufour JF, Flamm S, Firdoos S, Curry MP, Afdhal NH. The Optimal Timing of Hepatitis C Therapy in Transplant Eligible Patients With Child B and C Cirrhosis: A Cost-Effectiveness Analysis. Transplantation. 2017 05; 101(5):987-995. PMID: 27495755.
    Citations: 1     Fields:    Translation:Humans
  27. Iriana S, Curry MP, Afdhal NH. Neurologic Manifestations of Hepatitis C Virus Infection. Clin Liver Dis. 2017 08; 21(3):535-542. PMID: 28689591.
    Citations: 2     Fields:    Translation:Humans
  28. Afdhal N, Everson GT, Calleja JL, McCaughan GW, Bosch J, Brainard DM, McHutchison JG, De-Oertel S, An D, Charlton M, Reddy KR, Asselah T, Gane E, Curry MP, Forns X. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. J Viral Hepat. 2017 10; 24(10):823-831. PMID: 28295923.
    Citations: 3     Fields:    Translation:HumansCells
  29. Jacobson IM, Washington MK, Buti M, Thompson A, Afdhal N, Flisiak R, Akarca US, Tchernev KG, Flaherty JF, Aguilar Schall R, Myers RP, Subramanian GM, McHutchison JG, Younossi Z, Marcellin P, Patel K. Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral Therapy. Clin Gastroenterol Hepatol. 2017 Jul; 15(7):1087-1094.e2. PMID: 28215615.
    Citations:    Fields:    Translation:Humans
  30. Suresh M, Korolowicz KE, Balarezo M, Iyer RP, Padmanabhan S, Cleary D, Gimi R, Sheri A, Yon C, Kallakury BV, Tucker RD, Afdhal N, Menne S. Antiviral Efficacy and Host Immune Response Induction during Sequential Treatment with SB 9200 Followed by Entecavir in Woodchucks. PLoS One. 2017; 12(1):e0169631. PMID: 28056062.
    Citations: 3     Fields:    Translation:AnimalsCells
  31. Wyles D, Dvory-Sobol H, Svarovskaia ES, Doehle BP, Martin R, Afdhal NH, Kowdley KV, Lawitz E, Brainard DM, Miller MD, Mo H, Gane EJ. Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir. J Hepatol. 2017 04; 66(4):703-710. PMID: 27923693.
    Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
  32. Tapper EB, Bacon BR, Curry MP, Dieterich DT, Flamm SL, Guest LE, Kowdley KV, Lee Y, Tsai NC, Younossi ZM, Afdhal NH. Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study. J Viral Hepat. 2017 01; 24(1):22-27. PMID: 27730717.
    Citations: 8     Fields:    Translation:HumansCells
  33. Tapper EB, Bacon BR, Curry MP, Dieterich DT, Flamm SL, Guest LE, Kowdley KV, Lee Y, Tsai NC, Younossi ZM, Afdhal NH. Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study. Hepatology. 2016 12; 64(6):1893-1899. PMID: 27533287.
    Citations: 9     Fields:    Translation:HumansCells
  34. Afdhal NH, Serfaty L. Effect of Registries and Cohort Studies on HCV Treatment. Gastroenterology. 2016 09; 151(3):387-90. PMID: 27456388.
    Citations:    Fields:    Translation:Humans
  35. Younossi ZM, Stepanova M, Sulkowski M, Foster GR, Reau N, Mangia A, Patel K, Bräu N, Roberts SK, Afdhal N, Nader F, Henry L, Hunt S. Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials. Clin Infect Dis. 2016 10 15; 63(8):1042-1048. PMID: 27444413.
  36. Jiang ZG, Feldbrügge L, Tapper EB, Popov Y, Ghaziani T, Afdhal N, Robson SC, Mukamal KJ. Letter: would aspirin alleviate fibrosis in alcoholic liver disease? Authors' reply. Aliment Pharmacol Ther. 2016 07; 44(2):209-10. PMID: 27296690.
    Citations:    Fields:    Translation:Humans
  37. Sarrazin C, Dvory-Sobol H, Svarovskaia ES, Doehle BP, Pang PS, Chuang SM, Ma J, Ding X, Afdhal NH, Kowdley KV, Gane EJ, Lawitz E, Brainard DM, McHutchison JG, Miller MD, Mo H. Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir. Gastroenterology. 2016 09; 151(3):501-512.e1. PMID: 27296509.
    Citations: 36     Fields:    Translation:HumansCellsCTClinical Trials
  38. Patwardhan VR, Jiang ZG, Risech-Neiman Y, Piatkowski G, Afdhal NH, Mukamal K, Curry MP, Tapper EB. Serum Ammonia is Associated With Transplant-free Survival in Hospitalized Patients With Acutely Decompensated Cirrhosis [corrected]. J Clin Gastroenterol. 2016 04; 50(4):345-50. PMID: 26565968.
    Citations: 1     Fields:    Translation:HumansCells
  39. Kaswala DH, Lai M, Afdhal NH. Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016. Dig Dis Sci. 2016 May; 61(5):1356-64. PMID: 27017224.
    Citations: 10     Fields:    Translation:Humans
  40. Tapper EB, Challies T, Nasser I, Afdhal NH, Lai M. The Performance of Vibration Controlled Transient Elastography in a US Cohort of Patients With Nonalcoholic Fatty Liver Disease. Am J Gastroenterol. 2016 05; 111(5):677-84. PMID: 26977758.
    Citations: 6     Fields:    Translation:Humans
  41. Tapper EB, Sengupta N, Hunink MG, Afdhal NH, Lai M. Erratum: Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration-Controlled Transient Elastography. Am J Gastroenterol. 2016 Mar; 111(3):446. PMID: 27018125.
    Citations:    Fields:    
  42. Jiang ZG, Tapper EB, Connelly MA, Pimentel CF, Feldbrügge L, Kim M, Krawczyk S, Afdhal N, Robson SC, Herman MA, Otvos JD, Mukamal KJ, Lai M. Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease. Liver Int. 2016 08; 36(8):1213-20. PMID: 26815314.
    Citations: 3     Fields:    Translation:Humans
  43. Tapper EB, Hunink MG, Afdhal NH, Lai M, Sengupta N. Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score. PLoS One. 2016; 11(2):e0147237. PMID: 26905872.
    Citations: 5     Fields:    Translation:Humans
  44. Saab S, Park SH, Mizokami M, Omata M, Mangia A, Eggleton E, Zhu Y, Knox SJ, Pang P, Subramanian M, Kowdley K, Afdhal NH. Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older. Hepatology. 2016 Apr; 63(4):1112-9. PMID: 26704693.
    Citations: 18     Fields:    Translation:Humans
  45. Welzel TM, Reddy KR, Flamm SL, Denning J, Lin M, Hyland R, Pang PS, McHutchison JG, Charlton M, Everson GT, Zeuzem S, Afdhal N. On-treatment HCV RNA in patients with varying degrees of fibrosis and cirrhosis in the SOLAR-1 trial. Antivir Ther. 2016; 21(6):541-546. PMID: 26891418.
    Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
  46. Jiang ZG, Feldbrügge L, Tapper EB, Popov Y, Ghaziani T, Afdhal N, Robson SC, Mukamal KJ. Aspirin use is associated with lower indices of liver fibrosis among adults in the United States. Aliment Pharmacol Ther. 2016 Mar; 43(6):734-43. PMID: 26749582.
    Citations: 3     Fields:    Translation:Humans
  47. Tapper EB, Catana AM, Sethi N, Mansuri D, Sethi S, Vong A, Afdhal NH. Direct costs of care for hepatocellular carcinoma in patients with hepatitis C cirrhosis. Cancer. 2016 Mar 15; 122(6):852-8. PMID: 26716758.
    Citations: 6     Fields:    Translation:Humans
  48. Wilder JM, Jeffers LJ, Ravendhran N, Shiffman ML, Poulos J, Sulkowski MS, Gitlin N, Workowski K, Zhu Y, Yang JC, Pang PS, McHutchison JG, Muir AJ, Howell C, Kowdley K, Afdhal N, Reddy KR. Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data. Hepatology. 2016 Feb; 63(2):437-44. PMID: 26547499.
    Citations: 18     Fields:    Translation:HumansCTClinical Trials
  49. Foster GR, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S, Lawitz E, Thompson A, Shiffman ML, Cooper C, Towner WJ, Conway B, Ruane P, Bourlière M, Asselah T, Berg T, Zeuzem S, Rosenberg W, Agarwal K, Stedman CA, Mo H, Dvory-Sobol H, Han L, Wang J, McNally J, Osinusi A, Brainard DM, McHutchison JG, Mazzotta F, Tran TT, Gordon SC, Patel K, Reau N, Mangia A, Sulkowski M. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med. 2015 Dec 31; 373(27):2608-17. PMID: 26575258.
    Citations: 108     Fields:    Translation:HumansCellsCTClinical Trials
  50. Pimentel CF, Jiang ZG, Otsubo T, Feldbrügge L, Challies TL, Nasser I, Robson S, Afdhal N, Lai M. Poor Inter-test Reliability Between CK18 Kits as a Biomarker of NASH. Dig Dis Sci. 2016 Mar; 61(3):905-12. PMID: 26462489.
    Citations: 3     Fields:    Translation:Humans
  51. Tapper EB, Sengupta N, Hunink MG, Afdhal NH, Lai M. Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration Controlled Transient Elastography. Am J Gastroenterol. 2015 Sep; 110(9):1298-304. PMID: 26303130.
    Citations: 9     Fields:    Translation:Humans
  52. Giannini EG, Afdhal NH, Sigal SH, Muir AJ, Reddy KR, Vijayaraghavan S, Elkashab M, Romero-Gómez M, Dusheiko GM, Iyengar M, Vasey SY, Campbell FM, Theodore D. Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy. J Gastroenterol Hepatol. 2015 Aug; 30(8):1301-8. PMID: 25777337.
    Citations:    Fields:    Translation:Humans
  53. Alqahtani SA, Afdhal N, Zeuzem S, Gordon SC, Mangia A, Kwo P, Fried M, Yang JC, Ding X, Pang PS, McHutchison JG, Pound D, Reddy KR, Marcellin P, Kowdley KV, Sulkowski M. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials. Hepatology. 2015 Jul; 62(1):25-30. PMID: 25963890.
    Citations: 17     Fields:    Translation:HumansCellsCTClinical Trials
  54. Jain S, Rajasingham R, Noubary F, Coonahan E, Schoeplein R, Baden R, Curry M, Afdhal N, Kumar S, Pollock NR. Performance of an Optimized Paper-Based Test for Rapid Visual Measurement of Alanine Aminotransferase (ALT) in Fingerstick and Venipuncture Samples. PLoS One. 2015; 10(5):e0128118. PMID: 26020244.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  55. Sethi N, Tapper EB, Vong A, Sethi S, Rourke M, Afdhal NH. Direct costs of first-generation protease inhibitors for the treatment of genotype 1 chronic hepatitis C viral infection. J Viral Hepat. 2015 Dec; 22(12):974-6. PMID: 26010946.
    Citations:    Fields:    Translation:HumansCells
  56. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS, Fried MW, Terrault NA, O'Leary JG, Vargas HE, Kuo A, Schiff E, Sulkowski MS, Gilroy R, Watt KD, Brown K, Kwo P, Pungpapong S, Korenblat KM, Muir AJ, Teperman L, Fontana RJ, Denning J, Arterburn S, Dvory-Sobol H, Brandt-Sarif T, Pang PS, McHutchison JG, Reddy KR, Afdhal N. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology. 2015 Sep; 149(3):649-59. PMID: 25985734.
    Citations: 133     Fields:    Translation:HumansCellsCTClinical Trials
  57. Reddy KR, Bourlière M, Sulkowski M, Omata M, Zeuzem S, Feld JJ, Lawitz E, Marcellin P, Welzel TM, Hyland R, Ding X, Yang J, Knox S, Pang P, Dvory-Sobol H, Subramanian GM, Symonds W, McHutchison JG, Mangia A, Gane E, Mizokami M, Pol S, Afdhal N. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. Hepatology. 2015 Jul; 62(1):79-86. PMID: 25846144.
    Citations: 47     Fields:    Translation:HumansCellsCTClinical Trials
  58. Tapper EB, Afdhal NH. Vibration-controlled transient elastography: a practical approach to the noninvasive assessment of liver fibrosis. Curr Opin Gastroenterol. 2015 May; 31(3):192-8. PMID: 25730177.
    Citations: 6     Fields:    Translation:Humans
  59. Jiang ZG, Tsugawa Y, Tapper EB, Lai M, Afdhal N, Robson SC, Mukamal KJ. Low-fasting triglyceride levels are associated with non-invasive markers of advanced liver fibrosis among adults in the United States. Aliment Pharmacol Ther. 2015 Jul; 42(1):106-16. PMID: 25913437.
    Citations: 3     Fields:    Translation:Humans
  60. Younossi ZM, Stepanova M, Marcellin P, Afdhal N, Kowdley KV, Zeuzem S, Hunt SL. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials. Hepatology. 2015 Jun; 61(6):1798-808. PMID: 25627448.
    Citations: 27     Fields:    Translation:HumansCTClinical Trials